Clinical trials
Multiple Myeloma in Relapse clinical trials
Below are recruiting multiple myeloma in relapse clinical trials, each written for real people, not researchers. We’re tracking 209 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05160584Recruiting
Real-world treatment study for relapsed or refractory myeloma
This study follows people with multiple myeloma that has come back or stopped responding to treatment, and looks at how current care is used in real life. It may include people starting talquetamab, and aims to understand outcomes and treatment patterns outside of strict experimental settings.
LeobenAges 18 years+ - NCT06711705RecruitingPhase 2
Elranatamab for relapsed or refractory multiple myeloma
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06730256RecruitingEarly Phase 1
Cell therapy for hard-to-treat multiple myeloma and plasma cell leukemia
This study tests a new cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that is not responding to standard treatments or has come back. The therapy uses your own immune cells that are modified to fight the cancer.
Suzhou, JiangsuAges 18 years+ - NCT06732232RecruitingEarly Phase 1
CAR-T therapy for multiple myeloma that returned or didn't respond
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
ShanghaiAges 18–75 - NCT06759181RecruitingPhase 1/Phase 2
CAR-T targeting BCMA and FcRL5 for relapsed/refractory myeloma
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
XuzhouAges 18–70 - NCT06785415RecruitingPhase 1/Phase 2
Study of a drug combo for relapsed multiple myeloma
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
Rochester, MinnesotaAges 18 years+ - NCT06791681RecruitingEarly Phase 1
ESO-T01 for returning or hard-to-treat multiple myeloma
This trial tests a new treatment called ESO-T01 for people with multiple myeloma that has come back or is not responding to at least two prior therapies. It aims to see if this therapy is safe and can help control the disease.
Wuhan, HubeiAges 18 years+ - NCT06799026RecruitingPhase 1
Vaccine plus elranatamab for advanced multiple myeloma
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) mixed with myeloma cells, given together with a drug called elranatamab. It is for people with multiple myeloma that has not responded to at least three prior treatments.
Boston, MassachusettsAges 18 years+ - NCT06822972RecruitingPhase 2
Study of Selinexor Plus Bispecific Antibody for Resistant Myeloma
This study tests the drug selinexor in combination with a bispecific antibody for multiple myeloma that has already been treated with at least 4 prior therapies. The goal is to see if the combination is safe and effective for patients whose disease has returned or hasn’t responded to previous treatments.
Durham, North CarolinaAges 18 years+ - NCT06827860RecruitingPhase 2
Talquetamab shot for elderly with relapsed multiple myeloma
This study tests a new drug called talquetamab, given as a shot under the skin, for older adults with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if it can help control the cancer with fewer side effects.
New York, New YorkAges 70 years+ - NCT06832865RecruitingPhase 2
Elranatamab and isatuximab for relapsed multiple myeloma
This trial tests a combination of two drugs—elranatamab and isatuximab—for people with multiple myeloma that has come back or stopped responding to at least two prior treatments. The goal is to see if this new combination can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT06846905Recruiting
Cost and effects of raising the dose of myeloma drugs at home vs. hospital
This study compares whether raising the dose of your current bispecific antibody is more cost-effective when done as an outpatient (day hospital) or as an inpatient. It aims to find the best way to manage your treatment safely.
ToulouseAges 18 years+ - NCT06880393RecruitingPhase 2
BCMA CAR-T for high-risk multiple myeloma
This trial tests a new immunotherapy called BCMA CAR-T for people with multiple myeloma that is considered high-risk. It aims to see if this treatment can help patients who had a short response to initial therapy or have specific genetic changes in their cancer.
TianjinAges 18–75 - NCT06896916RecruitingPhase 1
Study of etentamig and a CELMoD drug for relapsed multiple myeloma
This trial tests a new combination of two drugs—etentamig given through a vein and a CELMoD pill—for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if this combination is safe and helps control the disease.
Beverly Hills, CaliforniaAges 18 years+ - NCT06934044RecruitingPhase 1
Cevostamab for Chinese patients with relapsed or refractory multiple myeloma
This trial tests a new drug called cevostamab for people with multiple myeloma that has come back or stopped responding to treatment. It aims to see how the drug works in the body, how safe it is, and if it helps control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06952478RecruitingPhase 3
Comparing a new injectable multiple myeloma drug to Darzalex Faspro
This trial compares a new injectable medicine (CT-P44) to an approved one (Darzalex Faspro), both given with lenalidomide and dexamethasone, for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if the new option works just as well.
Taipei, Beitou DistrictAges 18 years+ - NCT06971380RecruitingPhase 2
CAR-T therapy for multiple myeloma and amyloidosis
This trial tests a new CAR-T cell treatment (HBI0101) for people with multiple myeloma or light-chain amyloidosis that has come back or stopped responding to other treatments. The therapy uses your own immune cells to fight cancer, and the goal is to see if it can help control the disease.
JerusalemAges 18 years+ - NCT06988488RecruitingPhase 1/Phase 2
Study of mezigdomide plus elranatamab for relapsed multiple myeloma
This trial tests a combination of two drugs, mezigdomide (a pill) and elranatamab (an injection), for people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find the best dose and see if the combination is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT07018050RecruitingPhase 2
A study of a new combination for multiple myeloma
This study tests a new combination therapy for people with multiple myeloma that has returned or not responded to at least one prior treatment. The goal is to see if the combination (QLS32015 plus other drugs) can effectively control the cancer.
TianjinAges 18 years+ - NCT07032129RecruitingPhase 1/Phase 2
Targeted cell therapy for multiple myeloma that returned or didn't respond
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
Beijing, Beijing MunicipalityAges 21–90 - NCT07032714RecruitingPhase 1
Mezigdomide and talquetamab for relapsed multiple myeloma
This trial tests a combination of two drugs, mezigdomide (a pill) and talquetamab (an injection), for people with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to see if this combination can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT07051850Recruiting
Quality of life study for relapsed myeloma immunotherapy
This study compares quality of life and treatment results in people with relapsed or refractory multiple myeloma who receive either newer or standard immunotherapy. It aims to understand how these treatments affect daily living and outcomes.
Seocho, SeoulAges 19 years+ - NCT07093554RecruitingPhase 1
Talquetamab and Cilta-cel for relapsed multiple myeloma
This trial tests giving an immunotherapy drug (talquetamab) before CAR T-cell therapy (cilta-cel) to see if it helps people with multiple myeloma that has come back or stopped responding to other treatments.
Milwaukee, WisconsinAges 18 years+ - NCT07105059RecruitingPhase 1
Teclistamab and mezigdomide for multiple myeloma
This trial tests a combination of two drugs—teclistamab (an immunotherapy) and mezigdomide (a targeted pill)—for people with multiple myeloma that has come back or not responded to previous treatments. The goal is to see if this new combination can help when other options have stopped working.
Basking Ridge, New JerseyAges 18 years+
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple myeloma in relapse?
- Yes. Clin2 currently lists 209 recruiting multiple myeloma in relapse studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple myeloma in relapse trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple myeloma in relapse trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.